Clinical trials
Diabetes Mellitus, Type 2 trials in Serbia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 56 |
| Terminated | 4 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 37 |
| Sanofi | 4 |
| Boehringer Ingelheim | 3 |
| Gilead Sciences | 3 |
| Takeda | 3 |
| Hoffmann-La Roche | 2 |
| University of Belgrade | 2 |
| Aptabio Therapeutics, Inc. | 1 |
| Daiichi Sankyo | 1 |
| Genfit | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 65 |
| Diabetes Mellitus | 28 |
| Diabetic Nephropathies | 3 |
| Glucose Metabolism Disorders | 3 |
| Cardiovascular Diseases | 2 |
| Coronary Artery Disease | 2 |
| Diabetes Mellitus, Type 1 | 2 |
| Hyperglycemia | 2 |
| Metabolic Diseases | 2 |
| Renal Insufficiency, Chronic | 2 |
Trials
Showing 1 to 25 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.